PT1732512T - Formulação para inalação contendo uma sulfoalquileterciclodextrina e um corticosteroide - Google Patents
Formulação para inalação contendo uma sulfoalquileterciclodextrina e um corticosteroideInfo
- Publication number
- PT1732512T PT1732512T PT57049173T PT05704917T PT1732512T PT 1732512 T PT1732512 T PT 1732512T PT 57049173 T PT57049173 T PT 57049173T PT 05704917 T PT05704917 T PT 05704917T PT 1732512 T PT1732512 T PT 1732512T
- Authority
- PT
- Portugal
- Prior art keywords
- corticosteroid
- formulation containing
- sulfoalkyl ether
- ether cyclodextrin
- inhalant formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Nanotechnology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53362803P | 2003-12-31 | 2003-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1732512T true PT1732512T (pt) | 2017-07-24 |
Family
ID=34794240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT57049173T PT1732512T (pt) | 2003-12-31 | 2005-01-03 | Formulação para inalação contendo uma sulfoalquileterciclodextrina e um corticosteroide |
Country Status (15)
Country | Link |
---|---|
EP (4) | EP1732512B1 (pt) |
JP (6) | JP2007517067A (pt) |
KR (3) | KR20070007075A (pt) |
CN (3) | CN1976679B (pt) |
AU (3) | AU2004312096A1 (pt) |
BR (3) | BRPI0418386A (pt) |
CA (3) | CA2551749C (pt) |
DK (1) | DK1732512T3 (pt) |
HU (1) | HUE032527T2 (pt) |
IL (6) | IL176577A0 (pt) |
MX (2) | MX348041B (pt) |
NZ (1) | NZ548225A (pt) |
PT (1) | PT1732512T (pt) |
RU (3) | RU2388462C2 (pt) |
WO (3) | WO2005065435A2 (pt) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070020299A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
EP2708225B1 (en) | 2004-04-23 | 2018-12-26 | CyDex Pharmaceuticals, Inc. | DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin |
DE102005041860A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen |
EP2335707B1 (en) * | 2005-10-26 | 2015-05-06 | CyDex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
KR101274417B1 (ko) | 2005-11-09 | 2013-06-17 | 프로테올릭스, 인코퍼레이티드 | 효소 저해를 위한 화합물 |
CA2626122A1 (en) * | 2005-11-15 | 2007-05-24 | Baxter International, Inc. | Compositions comprising lipoxygenase inhibitors and cyclodextrin |
JP2009517460A (ja) * | 2005-12-02 | 2009-04-30 | アレムビック・リミテッド | プラミペキソールの安定化医薬組成物およびその製造方法 |
JP2009520823A (ja) * | 2005-12-20 | 2009-05-28 | ティカ レーケメデル アーベー | 薬物動態学的プロフィールの向上を有するコルチコステロイドを送達するための方法およびシステム |
DK2098248T3 (da) * | 2005-12-21 | 2012-09-17 | Meda Pharma Gmbh & Co Kg | Kombination af anticholinergika, glucocorticoider og beta2-agonister til behandling af inflammatoriske sygdomme |
PT1991201T (pt) * | 2006-02-10 | 2018-06-12 | Pari Pharma Gmbh | Antibióticos nebulizados para terapia de inalação |
WO2007095342A2 (en) * | 2006-02-15 | 2007-08-23 | Tika Läkemedel Ab | Stable corticosteroid mixtures |
PL2010220T3 (pl) * | 2006-04-03 | 2022-08-16 | Ceva Animal Health Pty Ltd | Stabilizowane preparaty polisiarczanu pentozanu (PPS) |
PT2041158E (pt) | 2006-06-19 | 2013-07-17 | Onyx Therapeutics Inc | Péptido epoxicetonas para inibição de proteassoma |
EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
EP1894559A1 (en) * | 2006-09-01 | 2008-03-05 | PARI Pharma GmbH | Means to solubilise steroids for inhalation |
US20090325917A1 (en) * | 2006-10-19 | 2009-12-31 | Cipla Limited | Pharmaceutical Compositions and Nasal Spray Incorporating Anhydrous Mometasone Furoate |
WO2008065142A1 (en) * | 2006-11-29 | 2008-06-05 | N.V. Organon | Stabilized solution of rocuronium comprising a sulfoalkyl-ether-beta-cyclodextrin derivative |
WO2008134601A1 (en) | 2007-04-27 | 2008-11-06 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin |
CN101795565A (zh) * | 2007-06-28 | 2010-08-04 | 锡德克斯药物公司 | 皮质类固醇水溶液的鼻部和眼部给药 |
HUE029665T2 (en) | 2007-10-04 | 2017-03-28 | Onyx Therapeutics Inc | Synthesis of crystalline peptide epoxy ketone protease inhibitors and amino acid keto epoxides \ t |
US20090149432A1 (en) * | 2007-11-09 | 2009-06-11 | Shrewsbury Stephen B | Methods for administering corticosteroid formulations |
EA035100B1 (ru) | 2008-10-21 | 2020-04-28 | Оникс Терапьютикс, Инк. | Комбинированная терапия с применением пептид эпоксикетонов |
WO2010053487A1 (en) | 2008-11-07 | 2010-05-14 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
US20100196483A1 (en) * | 2009-02-04 | 2010-08-05 | Activaero Gmbh Research & Development | Method for treatmentof severe and uncontrollable asthma |
RU2734236C2 (ru) * | 2009-02-25 | 2020-10-13 | Софткемо Фарма Корп. | Композиции бендамустина и циклополисахарида |
AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
WO2010132711A1 (en) | 2009-05-13 | 2010-11-18 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
ES2774391T3 (es) * | 2009-05-29 | 2020-07-20 | Pearl Therapeutics Inc | Composiciones, métodos y sistemas para la administración respiratoria de dos o más agentes activos |
BRPI1015046A2 (pt) | 2009-06-18 | 2016-04-12 | Allergan Inc | administração segura de desmopressina |
EP2498793B1 (en) | 2009-11-13 | 2019-07-10 | Onyx Therapeutics, Inc. | Oprozomib for use in metastasis suppression |
BR112012022060A2 (pt) | 2010-03-01 | 2018-05-08 | Onyx Therapeutics Inc | composto para a inibição de imunoproteassoma |
RU2445119C2 (ru) * | 2010-05-25 | 2012-03-20 | Сергей Викторович Чепур | Фармацевтическая композиция и способ ее ингаляционного введения |
CA2834063C (en) * | 2011-04-26 | 2016-01-05 | Activaero Gmbh | Administration of iloprost as aerosol bolus |
CN102188371B (zh) * | 2011-05-11 | 2013-01-23 | 台州职业技术学院 | 一种环索奈德纳米粒水溶液及其制备方法 |
CN102973574A (zh) * | 2011-09-02 | 2013-03-20 | 北京燕锋晨医药技术发展有限公司 | 一种用于治疗哮喘的药物组合物及制备方法 |
MX361886B (es) | 2012-05-08 | 2018-12-18 | Nicox Ophthalmics Inc | Preparaciones de agentes terapéuticos hidrófobos, métodos de elaboración y uso de los mismos. |
US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
PL2662094T3 (pl) * | 2012-05-08 | 2024-08-05 | Onyx Therapeutics, Inc. | Sposoby kompleksowania cylodekstryny do formułowania peptydowych inhibitorów proteasomu |
RU2504382C1 (ru) * | 2012-06-13 | 2014-01-20 | Шолекс Девелопмент Гмбх | Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения |
TW201414751A (zh) | 2012-07-09 | 2014-04-16 | 歐尼克斯治療公司 | 肽環氧酮蛋白酶抑制劑之前驅藥物 |
RU2506080C1 (ru) * | 2012-09-25 | 2014-02-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО НижГМА Минздравсоцразвития России) | Способ лечения и профилактики осложнений в полости рта, вызванных приемом ингаляционных гормональных препаратов у больных бронхиальной астмой |
RU2493827C1 (ru) * | 2012-10-03 | 2013-09-27 | Шолекс Девелопмент Гмбх | Стабильный комбинированный раствор фенотерола гидробромида и ипратропия бромида |
WO2014074797A1 (en) * | 2012-11-09 | 2014-05-15 | Civitas Therapeutics, Inc. | Ultra low density pulmonary powders |
US9815865B2 (en) | 2013-01-07 | 2017-11-14 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
EP2923702A1 (en) * | 2014-03-28 | 2015-09-30 | Universite De Liege | Composition of cyclodextrin with budesonide derivatives for treatment and prevention of pulmonary inflammatory disease |
ES2942710T3 (es) * | 2014-03-28 | 2023-06-06 | Univ Liege | Composición que comprende ciclodextrina y derivados de budesonida para su uso en el tratamiento y profilaxis de inflamaciones pulmonares |
EP3256216B1 (en) * | 2015-02-13 | 2023-09-06 | Vanderbilt University | Milrinone composition and method for administering same |
MA45276A (fr) * | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
WO2017193110A1 (en) * | 2016-05-06 | 2017-11-09 | Stites Adam | Cannabinoid compositions for sublingual spray nebulizer |
EP3464318B1 (en) | 2016-06-02 | 2021-04-21 | AbbVie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
US10772970B2 (en) | 2017-12-01 | 2020-09-15 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
EA202000218A1 (ru) * | 2018-01-23 | 2021-03-03 | Александр Григорьевич ЧУЧАЛИН | Фармацевтическая композиция (варианты), применение фармацевтической композиции (варианты) |
US11007185B2 (en) | 2019-08-01 | 2021-05-18 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
CN115835885A (zh) * | 2020-06-23 | 2023-03-21 | 广州谷森制药有限公司 | 包含奥达特罗和布地奈德的药物组合物的制备 |
WO2021262675A1 (en) * | 2020-06-23 | 2021-12-30 | Anovent Pharmaceutical (U.S.), Llc | Preparation of a pharmaceutical composition of olodaterol, tiotropium bromide and budesonide |
CN113018280A (zh) * | 2021-03-01 | 2021-06-25 | 石家庄四药有限公司 | 一种异丙托溴铵吸入用溶液制剂及其制备方法 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3008875A (en) * | 1960-01-08 | 1961-11-14 | Upjohn Co | Neomycin and mirystyl-gamma-picolinium halide compositions |
BE629985A (pt) * | 1962-11-29 | |||
US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
US5977070A (en) | 1992-07-14 | 1999-11-02 | Piazza; Christin Teresa | Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis |
US5324718A (en) | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
US5510339A (en) | 1993-02-02 | 1996-04-23 | Mayo Foundation For Medical Education And Research | Method for the treatment of bronchial asthma by administration of topical anesthetics |
US5525623A (en) | 1993-03-12 | 1996-06-11 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
DE69434304T2 (de) | 1993-03-26 | 2005-12-29 | Merkus, Franciscus Wilhelmus H.M. | Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin |
BE1007402A5 (nl) | 1993-03-26 | 1995-06-06 | Adir | Nasale farmaceutische preparaten met progestagene stof. |
TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
SK76797A3 (en) | 1994-12-22 | 1998-02-04 | Astra Ab | Therapeutic preparation for inhalation containing parathyroid hormone, pth |
DE4446891A1 (de) * | 1994-12-27 | 1996-07-04 | Falk Pharma Gmbh | Stabile wäßrige Budesonid-Lösung |
US5840713A (en) * | 1995-04-03 | 1998-11-24 | Weisz; Paul B. | Therapy for tissue membrane insufficiency |
US5576645A (en) * | 1995-06-05 | 1996-11-19 | Hughes Aircraft Company | Sample and hold flip-flop for CMOS logic |
US5677280A (en) | 1995-06-07 | 1997-10-14 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
US5683983A (en) | 1995-06-07 | 1997-11-04 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
US5654276A (en) | 1995-06-07 | 1997-08-05 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
US5668110A (en) | 1995-06-07 | 1997-09-16 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
US5750549A (en) | 1996-10-15 | 1998-05-12 | Merck & Co., Inc. | Cycloalkyl tachykinin receptor antagonists |
US5929094A (en) | 1996-10-25 | 1999-07-27 | Merck & Co., Inc. | Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists |
GB9625843D0 (en) | 1996-12-12 | 1997-01-29 | Merck & Co Inc | Phenyl spiroethercycloalkyl tachykinn receptor antagonists |
WO1998018827A1 (en) * | 1996-10-28 | 1998-05-07 | Farmarc Nederland B.V. | Inclusion complexes of beta-2-andrenergics for oral mucosal delivery |
US6071910A (en) | 1996-12-05 | 2000-06-06 | Mayo Foundation For Medical Education And Research | Use of agents to treat eosinophil-associated pathologies |
US5837713A (en) | 1997-02-26 | 1998-11-17 | Mayo Foundation For Medical Education And Research | Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids |
US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
DE69834154T2 (de) | 1997-07-01 | 2007-01-25 | Pfizer Products Inc., Groton | Verfahren zur Herstellung von einem Cyclodextrin |
JP2002509119A (ja) | 1998-01-13 | 2002-03-26 | アストラゼネカ ユーケイ リミテッド | ドーパミン(D2)レセプターアゴニスト活性を有する化合物およびβ2−アドレナリンレセプターアゴニスト活性を有する化合物(B)を含有する薬学的組成物 |
CA2320772A1 (en) | 1998-02-23 | 1999-08-26 | Cyclops, Ehf. | High-energy cyclodextrin complexes |
US6241969B1 (en) | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
JP2002523475A (ja) * | 1998-09-02 | 2002-07-30 | アラーガン・セイルズ・インコーポレイテッド | 防腐したシクロデキストリン含有組成物 |
US20020198174A1 (en) * | 2001-05-07 | 2002-12-26 | Allergan Sales, Inc. | Disinfecting and solubilizing steroid compositions |
AU2879100A (en) | 1999-02-12 | 2000-08-29 | Miles A. Libbey Iii | Formulation and system for intra-oral delivery of pharmaceutical agents |
FR2789685B1 (fr) | 1999-02-15 | 2001-05-04 | Univ Lille Sciences Tech | Procede de fabrication de polymeres solubles et insolubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s) et polymeres solubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s) |
US6136603A (en) | 1999-03-26 | 2000-10-24 | Isis Pharmaceuticals Inc. | Antisense modulation of interleukin-5 signal transduction |
MXPA02004193A (es) | 1999-10-29 | 2002-12-13 | Inhale Therapeutic Syst | Composiciones de polvo seco que tienen caracteristicas de dispersion mejoradas. |
US6479467B1 (en) | 1999-12-16 | 2002-11-12 | Eastman Chemical Company | Cyclodextrin ethers |
RU2180217C2 (ru) | 2000-03-21 | 2002-03-10 | Закрытое акционерное общество "Пульмомед" | Стабильный водный раствор противовоспалительного действия, содержащий будесонид |
AU2001255709A1 (en) | 2000-05-11 | 2001-11-20 | Eastman Chemical Company | Acylated cyclodextrin guest inclusion complexes |
AU2002241823A1 (en) | 2001-01-11 | 2002-07-24 | Eastman Chemical Company | Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials |
US7026304B2 (en) | 2001-02-14 | 2006-04-11 | Akzo Nobel N.V. | 2-alkylated-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
US20030055026A1 (en) * | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
CN1717209A (zh) | 2002-10-09 | 2006-01-04 | 植入疗法公司 | 以环糊精为基础的材料、其相关的组合物和用途 |
-
2004
- 2004-12-31 CA CA2551749A patent/CA2551749C/en active Active
- 2004-12-31 RU RU2006127443/15A patent/RU2388462C2/ru active
- 2004-12-31 NZ NZ548225A patent/NZ548225A/xx not_active IP Right Cessation
- 2004-12-31 JP JP2006547613A patent/JP2007517067A/ja not_active Withdrawn
- 2004-12-31 KR KR1020067015494A patent/KR20070007075A/ko not_active Application Discontinuation
- 2004-12-31 EP EP05704917.3A patent/EP1732512B1/en active Active
- 2004-12-31 WO PCT/US2005/000082 patent/WO2005065435A2/en active Application Filing
- 2004-12-31 RU RU2006127432/15A patent/RU2006127432A/ru not_active Application Discontinuation
- 2004-12-31 EP EP05704920A patent/EP1729724A4/en not_active Withdrawn
- 2004-12-31 EP EP17161913.3A patent/EP3238708A1/en not_active Withdrawn
- 2004-12-31 CN CN2004800422296A patent/CN1976679B/zh active Active
- 2004-12-31 AU AU2004312096A patent/AU2004312096A1/en not_active Abandoned
- 2004-12-31 KR KR1020067015501A patent/KR20070005586A/ko not_active Application Discontinuation
- 2004-12-31 AU AU2004312095A patent/AU2004312095A1/en not_active Abandoned
- 2004-12-31 CN CNA2004800422281A patent/CN1921830A/zh active Pending
- 2004-12-31 WO PCT/US2005/000085 patent/WO2005065649A1/en active Application Filing
- 2004-12-31 HU HUE05704917A patent/HUE032527T2/en unknown
- 2004-12-31 DK DK05704917.3T patent/DK1732512T3/en active
- 2004-12-31 AU AU2004311478A patent/AU2004311478A1/en not_active Abandoned
- 2004-12-31 CA CA002551826A patent/CA2551826A1/en not_active Abandoned
- 2004-12-31 KR KR1020067015502A patent/KR20070007076A/ko not_active Application Discontinuation
- 2004-12-31 BR BRPI0418386-0A patent/BRPI0418386A/pt not_active IP Right Cessation
- 2004-12-31 MX MX2015006104A patent/MX348041B/es unknown
- 2004-12-31 CA CA002552641A patent/CA2552641A1/en not_active Abandoned
- 2004-12-31 MX MXPA06007581A patent/MXPA06007581A/es active IP Right Grant
- 2004-12-31 CN CNA2004800422277A patent/CN1921834A/zh active Pending
- 2004-12-31 BR BRPI0418276A patent/BRPI0418276B8/pt active IP Right Grant
- 2004-12-31 RU RU2006127467/15A patent/RU2390330C2/ru active
- 2004-12-31 JP JP2006547615A patent/JP2007517069A/ja not_active Abandoned
- 2004-12-31 JP JP2006547614A patent/JP2007517068A/ja not_active Abandoned
-
2005
- 2005-01-03 BR BRPI0418232-4A patent/BRPI0418232A/pt not_active IP Right Cessation
- 2005-01-03 WO PCT/US2005/000084 patent/WO2005065651A1/en active Application Filing
- 2005-01-03 PT PT57049173T patent/PT1732512T/pt unknown
- 2005-01-03 EP EP05704919A patent/EP1718276A4/en not_active Withdrawn
-
2006
- 2006-06-27 IL IL176577A patent/IL176577A0/en unknown
- 2006-06-27 IL IL176575A patent/IL176575A0/en unknown
- 2006-06-27 IL IL176576A patent/IL176576A0/en unknown
-
2012
- 2012-08-24 JP JP2012184694A patent/JP5782413B2/ja active Active
-
2013
- 2013-04-25 IL IL251496A patent/IL251496B/en active IP Right Grant
- 2013-04-25 IL IL225946A patent/IL225946A/en active IP Right Grant
-
2015
- 2015-03-04 JP JP2015041915A patent/JP2015129173A/ja active Pending
-
2016
- 2016-07-05 JP JP2016133094A patent/JP6186478B2/ja active Active
-
2017
- 2017-04-02 IL IL251496A patent/IL251496A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL225946A0 (en) | Composition for inhalation containing sulfoalkyl ether cyclodextrin and corticosteroid | |
IL196185A0 (en) | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | |
IL179060A0 (en) | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin | |
IL178728A0 (en) | Dpi formulation containing sulfoalkyl ether cyclodextrin | |
EP1678211A4 (en) | SULFOALKYL ETHER-ALKYL ETHER CYCLODEXTRINS DERIVATIVES | |
EP1485110A4 (en) | USE OF SULFOALKYLETHER OF CYCLODEXTRIN AS A CONSERVATIVE AGENT | |
EP1383445A4 (en) | PREPARATION CONTAINING PROPOFOL AND SULFOALKYL ETHER CYCLODEXTRIN | |
AP3071A (en) | Ganaxolone formulations and methods for the makingand use thereof | |
EP2152078B8 (en) | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | |
IL176538A0 (en) | Steroid derivatives and pharmaceutical compositions containing the same | |
EP2286744B8 (en) | Tunnel notcher and guidewire delivery device | |
AU2003248862A1 (en) | Compositions and fabrication methods for hardmetals | |
EP1689372A4 (en) | COMPOSITIONS FOR CONJUGATED OESTROGENES AND ASSOCIATED METHODS | |
ZA200507351B (en) | Steroid spirolactonization | |
PL1626913T3 (pl) | Zastosowanie cyklezonidu do zachowywania frakcji drobnych cząstek formoterolu | |
IL174317A0 (en) | Triterpene derivatives and pharmaceutical compositions containing the same | |
AU2003265576A8 (en) | Corticosteroid conjugates and uses thereof | |
EP1622572A4 (en) | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | |
EP1594515A4 (en) | FORMULATION AND ADMINISTRATION OF A MEDICINAL PRODUCT USING METHYLATED CRYSTALLINE CYCLODEXTRINS | |
GB2400654B (en) | Particle size distribution analyzer | |
AU2003264519A1 (en) | Deodorant agent | |
AU2003300438A1 (en) | Ether compounds and compositions for cholesterol management and related uses | |
AU2003255143A1 (en) | Antiallergic agent containing ground lotus or lotus extract | |
AU2003279282A1 (en) | Methods and compositions for the treament of cancer | |
AU2003903273A0 (en) | Fine particle mixer |